These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 30194778)

  • 1. The addition of lymphadenectomy to secondary cytoreductive surgery in comparison with bulky node resection in patients with recurrent ovarian cancer.
    Bogani G; Leone Roberti Maggiore U; Chiappa V; Ditto A; Martinelli F; Sabatucci I; Mosca L; Lorusso D; Raspagliesi F
    Int J Gynaecol Obstet; 2018 Dec; 143(3):319-324. PubMed ID: 30194778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiophrenic lymph node resection in cytoreduction for primary advanced or recurrent epithelial ovarian carcinoma: a cohort study.
    Lopes A; Rangel Costa RL; di Paula R; Anton C; Calheiros Y; Sartorelli V; Kanashiro YM; de Lima JA; Yamada A; Pinto GLS; Vianna MR; Nogueira Dias Genta ML; Ribeiro U; Dos Santos MO
    Int J Gynecol Cancer; 2019 Jan; 29(1):188-194. PubMed ID: 30640703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bulky lymph node resection in patients with recurrent epithelial ovarian cancer: impact of surgery.
    Benedetti Panici P; Perniola G; Angioli R; Zullo MA; Manci N; Palaia I; Bellati F; Plotti F; Calcagno M; Basile S
    Int J Gynecol Cancer; 2007; 17(6):1245-51. PubMed ID: 17425680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Secondary cytoreductive surgery in patients presenting with isolated nodal recurrence of epithelial ovarian cancer.
    Fotiou S; Aliki T; Petros Z; Ioanna S; Konstantinos V; Vasiliki M; George C
    Gynecol Oncol; 2009 Aug; 114(2):178-82. PubMed ID: 19450872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secondary cytoreductive surgery for isolated lymph node recurrence of epithelial ovarian cancer: a multicenter study.
    Ferrero A; Ditto A; Giorda G; Gadducci A; Greggi S; Daniele A; Fuso L; Panuccio E; Scaffa C; Raspagliesi F; Sismondi P; Biglia N
    Eur J Surg Oncol; 2014 Jul; 40(7):891-8. PubMed ID: 24378007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Salvage lymphadenectomy in recurrent ovarian cancer patients: Analysis of clinical outcome and BRCA1/2 gene mutational status.
    Gallotta V; Bruno M; Conte C; Giudice MT; Davià F; Moro F; Zannoni GF; Fagotti A; De Bonis M; Capoluongo E; Scambia G; Ferrandina G
    Eur J Surg Oncol; 2020 Jul; 46(7):1327-1333. PubMed ID: 32085925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secondary cytoreductive surgery for isolated nodal recurrence in patients with epithelial ovarian cancer.
    Santillan A; Karam AK; Li AJ; Giuntoli R; Gardner GJ; Cass I; Karlan BY; Bristow RE
    Gynecol Oncol; 2007 Mar; 104(3):686-90. PubMed ID: 17141302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secondary cytoreductive surgery in recurrent epithelial ovarian cancer: A prognostic analysis with 103 cases.
    Fan XM; Zhang J; Niu SH; Li KX; Song CZ
    Int J Surg; 2017 Feb; 38():61-66. PubMed ID: 28027999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secondary cytoreductive surgery - viable treatment option in the management of platinum-sensitive recurrent ovarian cancer.
    Felsinger M; Minar L; Weinberger V; Rovny I; Zlamal F; Bienertova-Vasku J
    Eur J Obstet Gynecol Reprod Biol; 2018 Sep; 228():154-160. PubMed ID: 29957400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of cytoreductive surgery on survival of patients with recurrent epithelial ovarian cancer.
    Zang RY; Zhang ZY; Li ZT; Chen J; Tang MQ; Liu Q; Cai SM
    J Surg Oncol; 2000 Sep; 75(1):24-30. PubMed ID: 11025458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Laparoscopic Management of Ovarian Cancer Patients With Localized Carcinomatosis and Lymph Node Metastases: Results of a Retrospective Multi-institutional Series.
    Gallotta V; Ghezzi F; Vizza E; Fagotti A; Ceccaroni M; Fanfani F; Chiantera V; Ercoli A; Rossitto C; Conte C; Uccella S; Corrado G; Scambia G; Ferrandina G
    J Minim Invasive Gynecol; 2016; 23(4):590-6. PubMed ID: 26872630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of systematic lymphadenectomy as part of primary debulking surgery for optimally cytoreduced advanced ovarian cancer: Reappraisal in the era of radical surgery.
    Eoh KJ; Lee JY; Yoon JW; Nam EJ; Kim S; Kim SW; Kim YT
    Oncotarget; 2017 Jun; 8(23):37807-37816. PubMed ID: 27906676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Artificial intelligence weights the importance of factors predicting complete cytoreduction at secondary cytoreductive surgery for recurrent ovarian cancer.
    Bogani G; Rossetti D; Ditto A; Martinelli F; Chiappa V; Mosca L; Leone Roberti Maggiore U; Ferla S; Lorusso D; Raspagliesi F
    J Gynecol Oncol; 2018 Sep; 29(5):e66. PubMed ID: 30022630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Minimally invasive salvage lymphadenectomy in gynecological cancer patients: A single institution series.
    Gallotta V; Giudice MT; Conte C; Sarandeses AV; D'Indinosante M; Federico A; Tortorella L; Carbone MV; Gueli Alletti S; Vizzielli G; Costantini B; Scambia G; Ferrandina G
    Eur J Surg Oncol; 2018 Oct; 44(10):1568-1572. PubMed ID: 30170883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of systematic lymphadenectomy at the time of interval debulking surgery for patients with advanced-stage epithelial ovarian carcinoma who achieved complete gross resection.
    Nasioudis D; Gysler S; Latif NA; Giuntoli RL; Kim SH; Ko EM
    Int J Gynecol Cancer; 2024 Jul; 34(7):969-974. PubMed ID: 38754968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic impact of celiac lymph node involvement in patients after frontline treatment for advanced ovarian cancer.
    Angeles MA; Ferron G; Cabarrou B; Balague G; Martínez-Gómez C; Gladieff L; Pomel C; Martinez A
    Eur J Surg Oncol; 2019 Aug; 45(8):1410-1416. PubMed ID: 30857876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncologic outcomes after secondary surgery in recurrent clear-cell carcinoma of the ovary.
    Kajiyama H; Suzuki S; Yoshikawa N; Kawai M; Shibata K; Nagasaka T; Kikkawa F
    Int J Gynecol Cancer; 2019 Jun; 29(5):910-915. PubMed ID: 30839284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perioperative morbidity and outcome of secondary cytoreduction for recurrent epithelial ovarian cancer.
    Woelber L; Jung S; Eulenburg C; Mueller V; Schwarz J; Jaenicke F; Mahner S
    Eur J Surg Oncol; 2010 Jun; 36(6):583-8. PubMed ID: 20488646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of secondary cytoreductive surgery for recurrent mucinous epithelial ovarian cancer (mEOC).
    Cheng X; Jiang R; Li ZT; Tang J; Cai SM; Zhang ZY; Tian WJ; Zang RY
    Eur J Surg Oncol; 2009 Oct; 35(10):1105-8. PubMed ID: 19443175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lymph node-positive stage IIIC ovarian cancer: a separate entity?
    Berek JS
    Int J Gynecol Cancer; 2009 Dec; 19 Suppl 2():S18-20. PubMed ID: 19955908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.